Ultragenyx Pharmaceutical Inc. Files 8-K with Officer, Director, and Compensation Updates
Ticker: RARE · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-appointment, director-election
Related Tickers: RARE
TL;DR
Ultragenyx filed an 8-K: new directors elected, officers appointed, compensation plans updated, and shareholder votes confirmed.
AI Summary
On June 18, 2024, Ultragenyx Pharmaceutical Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for its officers. Additionally, the filing confirms the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance structure, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and does not appear to disclose any significant new risks or negative financial developments.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- June 18, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors?
The filing indicates the election of directors but does not name the specific individuals in the provided text.
What specific compensatory arrangements were updated for officers?
The filing mentions updates to compensatory arrangements but does not provide specific details on the changes in the provided text.
What matters were submitted to a vote of security holders?
The filing confirms the submission of matters to a vote of security holders but does not specify the nature of these matters in the provided text.
When was the report filed?
The report was filed on June 21, 2024, with the earliest event reported on June 18, 2024.
What is Ultragenyx Pharmaceutical Inc.'s principal executive office address?
The principal executive offices are located at 60 Leveroni Court, Novato, California, 94949.
Filing Stats: 836 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-06-21 16:05:32
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
Filing Documents
- rare-20240618.htm (8-K) — 62KB
- rare-ex10_1.htm (EX-10.1) — 125KB
- 0000950170-24-076222.txt ( ) — 318KB
- rare-20240618.xsd (EX-101.SCH) — 23KB
- rare-20240618_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, the Company held its Annual Meeting. As of the record date of April 23, 2024, 83,133,341 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. A total of 78,535,662 shares of the Company's common stock were represented in person or by proxy at the Annual Meeting. Proposal No. 1 – Election of Class II Directors At the Annual Meeting, the Company's stockholders elected the Class II director nominees below to the Company's Board of Directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class II Director Nominees Votes For Votes Withheld Broker Non-Votes Deborah Dunsire, M.D. 66,396,499 7,865,348 4,273,815 Michael Narachi 66,013,202 8,248,645 4,273,815 Corsee Sanders, Ph.D. 68,077,817 6,184,030 4,273,815 Proposal No. 2 – Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 51,942,752 22,299,718 19,377 4,273,815 Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions 77,155,452 1,362,194 18,016 Proposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described in the Proxy Statement. The votes on Proposal 4 were as follo
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amended and Restated 2023 Incentive Plan 104 The cover page from the Company's Current Report on Form 8-K dated June 18, 2024 formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: June 21, 2024 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy